Status:
COMPLETED
Immunogenicity Bridge Between an Investigational Monovalent Vaccine and the Equivalent Component of Gardasil (V501) a Quadrivalent Vaccine (V501-012)(COMPLETED)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Cervical Cancer
Genital Warts
Eligibility:
FEMALE
16-23 years
Phase:
PHASE3
Brief Summary
The purpose of the study is to determine if an investigational vaccine with a single component develops an immune response that is similar to the equivalent investigational vaccine with four component...
Eligibility Criteria
Inclusion
- Female with an intact uterus with lifetime history of 0-4 sexual partners
Exclusion
- Prior Human Papillomavirus Vaccine (HPV) vaccination;
- Prior abnormal paps;
- Prior history of genital warts
Key Trial Info
Start Date :
June 28 2002
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 15 2008
Estimated Enrollment :
3882 Patients enrolled
Trial Details
Trial ID
NCT00092482
Start Date
June 28 2002
End Date
August 15 2008
Last Update
March 22 2017
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.